Biomarin Pharmaceutical Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Biomarin Pharmaceutical Inc in the second quarter 2026?
Biomarin Pharmaceutical Inc achieved a return on average equity (ROE) of 1.18 % in its second quarter 2026, this is above BMRN's average return on equity of -0.68%.
Biomarin Pharmaceutical Incs equity during the 12 months ending in the second quarter 2026 are valued at $6 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 59 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1991 to 2033.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	4.89 %	7.23 %	7.58 %	11.88 %	-
Y / Y Net Income Change	-81.39 %	-43.17 %	-	-	124.43 %
Net Income (TTM) in Millions	73	269	349	520	657
Return On Equity (TTM)	1.18 %	4.41 %	5.82 %	8.84 %	11.48 %
BMRN's Total Ranking	# 2033	# 1991	# 1333	# 1406	# 920
Equity (TTM) in Millions	6,322	6,212	6,087	6,057	6,027
Seq. Equity Change	1.76 %	2.06 %	0.5 %	0.49 %	4.03 %
Seq. Net Income Change	-57.58 %	-	-	-	29.54 %

Back to BMRN Management Effectiveness >> BMRN's 5 Years Annual ROE >> Compare BMRN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 60
Sector	# 183
Overall	# 2033

Return On Equity Statistics
High	Average	Low
42.23 %	-0.68 %	-25.71 %
(Mar 31 2011)		(Dec 31 2016)

BMRN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	6,087	5,658	4,952	4,603	4,271
Y / Y Equity Change	7.58 %	14.27 %	7.57 %	7.78 %	4.01 %
Net Income in Millions	349	427	168	142	-64
Y / Y Net Income Change	-18.26 %	154.62 %	18.43 %	-	-
Return On Equity	5.73 %	7.54 %	3.39 %	3.08 %	-1.5 %

Back to BMRN Management Effectiveness >> BMRN's 5 Years Annual ROE >> Compare BMRN ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 5.73 %, due to deterioration of net income.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BMRN's' Return on Equity at Yahoo Finance
BMRN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BMRN's Competitors
Subscribers only: Roe for Biomarin Pharmaceutical Inc's Suppliers
Subscribers only: Return On Equity for BMRN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Bio rad Laboratories Inc	3.15 %
Envista Holdings Corporation	3.08 %
Immucell Corporation	2.68 %
Surgery Partners Inc	2.63 %
Mimedx Group Inc	2.61 %
Cormedix Inc	2.18 %
Atricure Inc	2.14 %
Pacira Biosciences inc	2.13 %
Warby Parker Inc	2.06 %
Repligen Corp	1.98 %
Arvinas Inc	1.91 %
Waters Corporation	1.88 %
Omada Health Inc	1.84 %
Radnet Inc	1.42 %
Icu Medical Inc	1.41 %
Biomarin Pharmaceutical Inc	1.18 %
Staar Surgical Co	1.08 %
Champions Oncology Inc	0.94 %
Delcath Systems Inc	0.46 %

Date modified: 2026-09-12T06:12:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.